Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Timothy Carey

Orthopaedic Surgery Manhattan, KS Doctor of Osteopathy

NPI 1962659060 CMS profile 44409

5782 Elbo Ridge Dr, Manhattan, KS 66502

Open in the dashboard

General payments

$37,970

145 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Timothy Carey of Manhattan, KS is reported in the CMS Open Payments database as having received $37,970 across 145 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 87th percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,032 13
2024 General $2,066 21
2023 General $3,697 11
2022 General $17,848 29
2021 General $8,338 35
2020 General $4,058 17
2019 General $931 19

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Timothy Carey
  • Orthopaedic Surgery median
  • Middle half of Orthopaedic Surgery
  • National median

In program year 2025, general payments to Timothy Carey were reported at $1,032. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.

Show as a table
Year Timothy Carey Orthopaedic Surgery median Middle half National median
2019 $931 $644 $140–$2,844 $163
2020 $4,058 $312 $75–$1,860 $114
2021 $8,338 $520 $117–$2,495 $132
2022 $17,848 $598 $128–$2,731 $149
2023 $3,697 $461 $128–$2,264 $160
2024 $2,066 $497 $134–$2,475 $164
2025 $1,032 $563 $147–$2,717 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medical Device Business Services, Inc. $24,241 28 payments
  2. Stryker Corporation $5,547 48 payments
  3. Smith+Nephew, Inc. $4,578 9 payments
  4. Biocomposites Inc $960 6 payments
  5. Ethicon US, LLC $840 22 payments
  6. Alaska Medical Technologies, LLC $516 2 payments
  7. DePuy Synthes Sales Inc. $341 6 payments
  8. Acumed LLC $198 5 payments
  9. Endo Pharmaceuticals Inc. $132 4 payments
  10. Innovation Technologies Inc $123 1 payment
  11. Other $494 14 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $20,000 11 payments
  2. Travel and Lodging $12,250 27 payments
  3. Food and Beverage $5,459 104 payments
  4. Education $261 3 payments
Products named General payments · program years 2019–2025
  1. DERMABOND $16,969 12 payments
  2. STRATAFIX Wound Closure $16,412 17 payments
  3. STRATAFIX Wound Closure $3,447 6 payments
  4. ANTHOLOGY $3,364 6 payments
  5. DERMABOND Portfolio $3,325 2 payments
  6. SALVATION $1,315 5 payments
  7. ICONIX $1,077 2 payments
  8. POLARSTEM $1,058 4 payments
  9. OR3O Dual Mobility $1,058 4 payments
  10. TANDEM $1,058 4 payments
  11. Other $8,076 110 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 70 billing codes

Paid by Medicare

$88,308

Of which drugs: $14,691

Medicare patients

271

Average age 70

Services billed

9,020

151 women, 120 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 73%
High blood pressure 63%
Diabetes 25%
Ischemic heart disease 17%
Depression 16%
Chronic kidney disease 15%
COPD 14%
Atrial fibrillation 13%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, trivisc, for intra-articular injection, 1 mg J7329 Office 49 2,425 $13,473
Injection, methylprednisolone acetate, 1 mg J1010 Office 66 5,581 $561
Injection, methylprednisolone acetate, 80 mg J1040 Office 24 26 $182

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Exparel
  • Pacira Pharmaceuticals Incorporated $14
$14 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

145 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery in Kansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record